Publication
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Pancreatic Neoplasmcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF N486_P490delcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29903880
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF N486_P490del1 | ||||||||
| Trametinib | Malignant Pancreatic Neoplasm | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7730In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib. Within 4 weeks of initiating therapy, her serum CA19-9 had fallen from 36,000 to 8,100 U/mL,… (full text at CIViC) PMID 29903880 · Aguirre et al., 2018 · Open in CIViC | civic |
| MAP2K2 H123Q1 | ||||||||
| Trametinib | Malignant Pancreatic Neoplasm | Predictive | C | Supports Resistance | 2 | submitted | EID7731In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC) PMID 29903880 · Aguirre et al., 2018 · Open in CIViC | civic |
| MAP2K2 G132D1 | ||||||||
| Trametinib | Pancreatic Adenocarcinoma | Predictive | C | Supports Resistance | 2 | submitted | EID7732In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC) PMID 29903880 · Aguirre et al., 2018 · Open in CIViC | civic |
| MAP2K2 G132S1 | ||||||||
| Trametinib | Pancreatic Adenocarcinoma | Predictive | C | Supports Resistance | 2 | submitted | EID7733In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC) PMID 29903880 · Aguirre et al., 2018 · Open in CIViC | civic |